Report Emphasizes Importance of Consumer Involvement in Tobacco Harm Reduction Strategies

Aug.30.2023
Report Emphasizes Importance of Consumer Involvement in Tobacco Harm Reduction Strategies
The Coalition of Asia Pacific Harm Reduction Advocates (CAPHRA) released a report emphasizing the need for consumer involvement in tobacco harm reduction policies.

According to a report by the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) released on August 29th, the "Framework Convention on Tobacco Control" emphasizes the necessity of consumer participation in the development of policies aimed at reducing tobacco harm.


The Asia-Pacific Coalition for Tobacco Harm Reduction (APCTHR) announced this week the release of this report. The report has now been made available to policymakers, regulatory agencies in member countries, and officials from the World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC).


The report emphasizes the importance of consumer engagement in policy making and highlights the benefits of alternative solutions, such as e-cigarettes, in reducing the harm caused by tobacco.


Tobacco harm reduction products have been proven to be a method of quitting smoking and an alternative solution for smokers who are unable or unwilling to quit completely," said Nancy Loucas, a renowned public health consumer advocate and Executive Coordinator of CAPHRA in New Zealand.


The World Health Organization's Framework Convention on Tobacco Control aims to be an evidence-based treaty that reaffirms everyone's right to the highest standard of health. However, current tobacco control measures heavily promote quitting smoking only, which prohibits smokers from making informed choices about safer nicotine products," added Nancy Loucas.


This report calls for the adoption of more compassionate, person-centered, choice-based, and rights-based tobacco control methods. By involving consumers in the development of healthcare policies and research, clinical practice guidelines, and patient information materials, the quality of health information and outcomes for individuals using tobacco harm reduction products can be enhanced.


References:


Article 1 (d) of the Framework Convention on Tobacco Control (FCTC) emphasizes the importance of adopting harm reduction strategies in the fight against tobacco use. The FCTC, a global public health treaty, aims to address the devastating impact of tobacco consumption on individuals and societies. Harm reduction strategies refer to approaches that focus on minimizing the adverse health effects associated with tobacco use, while acknowledging that complete eradication may not be immediately achievable. This article recognizes the need for alternatives to conventional tobacco products that can potentially reduce the harm caused by smoking. These harm reduction strategies include measures such as promoting the use of less harmful alternatives like nicotine replacement therapies, electronic nicotine delivery systems (e-cigarettes), and other non-combustible tobacco products. The goal is to encourage individuals to switch to less harmful options and ultimately reduce the number of people addicted to traditional cigarettes. While it is crucial to implement these harm reduction measures, Article 1 (d) also underscores the importance of maintaining strong regulatory controls to prevent the tobacco industry from exploiting these strategies. The FCTC emphasizes the need for evidence-based policies, in line with the latest scientific research, to ensure that harm reduction measures are effectively implemented and do not unintentionally lead to increased tobacco use. Overall, Article 1 (d) of the FCTC highlights the significance of adopting harm reduction strategies as a means to combat the harmful effects of tobacco. By prioritizing the reduction of harm associated with tobacco use and promoting the use of less harmful alternatives, there is a possibility to protect public health and mitigate the devastating consequences of tobacco consumption on individuals and communities.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-founded online nicotine pouch retailer GotPouches has completed the localization of its U.S. operations under UpNorth Retail LLC, with corporate operations in Franklin, Tennessee, domestic fulfillment from Nashville and U.S.-based customer support. The company says its catalog covers more than 20 nicotine pouch brands and it currently serves customers in more than 25 U.S. states.
Sep.18
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company has begun selling four flavored Vuse Pro pods — Peach, Berry, Watermelon and Fresh Mint — in Ohio and selected other U.S. markets. According to the Vuse U.S. FAQ, Vuse Pro contains approximately 5.0% nicotine by weight, and Vuse Pro pre-filled pods are intended for use with Vuse Alto devices. Reynolds told 2Firsts that product labeling lists an e-liquid capacity of 2.0 mL per pod. The Vuse Alto Power Unit received FDA marketing authorization in 2024, while the new Vuse Pro pods themselves have not received marketing granted orders. The rollout follows the FDA’s May 2026 revision of enforcement priorities for certain unauthorized vaping products with qualifying pending applications.
BAT
Sep.10
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
AIR’s first half-year results as a listed company offer a new test of how far a traditional hookah business can transform. H1 2026 revenue rose 3.7%, even as Flavored Shisha Molasses shipments fell 9%, with pricing and mix supporting growth. Traditional shisha still generates almost all revenue, while OOKA, Crown Switch, Greentank and U.S. regulatory spending point to accelerating diversification. The next test is whether those investments can become a second business of meaningful scale and profitability.
Capital Markets
Aug.21